433 related articles for article (PubMed ID: 27045874)
1. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Park SH; Jeong MH; Park IH; Choi JS; Rhee JA; Kim IS; Kim MC; Cho JY; Sim DS; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
Int J Cardiol; 2016 Jun; 212():100-6. PubMed ID: 27045874
[TBL] [Abstract][Full Text] [Related]
2. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
4. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
5. Association of radial versus femoral access with contrast-induced acute kidney injury in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Kolte D; Spence N; Puthawala M; Hyder O; Tuohy CP; Davidson CB; Sheldon MW; Laskey WK; Abbott JD
Cardiovasc Revasc Med; 2016 Dec; 17(8):546-551. PubMed ID: 27566903
[TBL] [Abstract][Full Text] [Related]
6. A comparison between two different definitions of contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Ferrante G; Acquaviva R; Castini D; Spina M; Lombardi F; Cozzolino M; Carugo S
Int J Cardiol; 2016 May; 210():4-9. PubMed ID: 26921538
[TBL] [Abstract][Full Text] [Related]
7. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
8. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention.
Lin KY; Zheng WP; Bei WJ; Chen SQ; Islam SM; Liu Y; Xue L; Tan N; Chen JY
Int J Cardiol; 2017 Mar; 230():402-412. PubMed ID: 28043662
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Dai Y; Huang J; Zeng L; Huang Z; Duan C; Shao S; Chen H; Xue L; Chen J; Tan N; He P; Liu Y; Yu D
Biomed Pharmacother; 2020 Aug; 128():110336. PubMed ID: 32521452
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Zhao SJ; Zhong ZS; Qi GX; Tian W
Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
[TBL] [Abstract][Full Text] [Related]
11. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.
Nakahashi H; Kosuge M; Sakamaki K; Kiyokuni M; Ebina T; Hibi K; Tsukahara K; Iwahashi N; Kuji S; Oba MS; Umemura S; Kimura K
Heart Vessels; 2017 Jan; 32(1):22-29. PubMed ID: 27106917
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
[TBL] [Abstract][Full Text] [Related]
13. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
14. Acute Kidney Injury After Primary Angioplasty: Is Contrast-Induced Nephropathy the Culprit?
Caspi O; Habib M; Cohen Y; Kerner A; Roguin A; Abergel E; Boulos M; Kapeliovich MR; Beyar R; Nikolsky E; Aronson D
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28647690
[TBL] [Abstract][Full Text] [Related]
15. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
16. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study.
Leone AM; De Caterina AR; Sciahbasi A; Aurelio A; Basile E; Porto I; Trani C; Burzotta F; Niccoli G; Mongiardo R; Mazzari MA; Buffon A; Panocchia N; Romagnoli E; Lioy E; Rebuzzi AG; Crea F
EuroIntervention; 2012 Nov; 8(7):839-47. PubMed ID: 23171803
[TBL] [Abstract][Full Text] [Related]
17. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
[TBL] [Abstract][Full Text] [Related]
18. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
19. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Çınar T; Tanık VO; Aruğaslan E; Karabağ Y; Çağdaş M; Rencüzoğulları İ; Keskin M
Cardiovasc Interv Ther; 2019 Jul; 34(3):207-215. PubMed ID: 30191494
[TBL] [Abstract][Full Text] [Related]
20. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
